Natera, Inc. ($NTRA) Stock Forecast: Up 5.1% Today

What is Natera, Inc.?

Natera, Inc. (NASDAQ: NTRA) operates in the fields of cell-free DNA and precision medicine covering oncology, women's health, and organ health. The stock of NTRA displayed significant bullish movement recently.

Why is Natera, Inc. going up?

NTRA stock is up 5.1% on Apr 30, 2026 16:11

• The company revealed its first-quarter financial results and held a conference call, potentially boosting investor confidence and fueling the bullish movement.
• Insider selling by the co-founder and CEO, aimed at covering tax obligations, initially raised concerns but a clarified context of these sales being part of a pre-arranged trading plan may have alleviated any negative impact.
• Despite Natera's current lack of profitability, positive court rulings and new analyst coverage could have positively influenced investor sentiment, contributing to the bullish market performance.
• Taken together, positive updates on financial results, structured insider trading activities, and external factors like court decisions and analyst coverage likely played a role in Natera's recent strong bullish trend.

NTRA Price Chart

NTRA Technical Analysis

NTRA News

After the close, Natera will post Q1 results and host a 4:30 ET call

Natera, Inc. (NASDAQ: NTRA) announced that it will release its first-quarter 2026 financial results after market close on May 7, 2026. This will be followed by a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET). The call will provide details on the company's financial performance for the quarter ended March 31, 2026.

https://www.stocktitan.net/news/NTRA/natera-to-report-its-first-quarter-results-on-may-7-4f2w90kkmeml.html

Natera to Report its First Quarter Results on May 7, 2026

Natera, Inc. announced it will release its first quarter 2026 financial results after market close on May 7, 2026. The company will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) on the same day to discuss the results. Natera specializes in cell-free DNA and precision medicine across oncology, women's health, and organ health.

https://markets.financialcontent.com/stocks/article/bizwire-2026-4-30-natera-to-report-its-first-quarter-results-on-may-7-2026

Natera co-founder Sheena Jonathan sells $699,692 in company stock

Natera co-founder Sheena Jonathan has sold company common stock worth $699,692 through transactions on April 27 and April 29, 2026. These sales, executed at prices ranging from $196.2151 to $204.39 per share, were partly to cover tax obligations from vested Restricted Stock Units and partly under a Rule 10b5-1 trading plan. Despite Natera's strong revenue growth, the company remains unprofitable, with insider activity coinciding with recent favorable court decisions and new analyst coverage.

https://m.investing.com/news/insider-trading-news/natera-cofounder-sheena-jonathan-sells-699692-in-company-stock-93CH-4647551?ampMode=1

Natera (NTRA) president sells 2,182 shares to cover RSU taxes

Natera's President, Clinical Diagnostics, Solomon Moshkevich, sold 2,182 shares of Natera common stock on April 27, 2026, for approximately $204 per share. These sales totaling $445,341 were exclusively conducted to satisfy tax withholding obligations related to the vesting of Restricted Stock Units (RSUs) granted in January 2023 and January 2024. The transactions were initiated under a Rule 10b5-1(c) plan, indicating a pre-planned tax-related disposition rather than a discretionary sale.

https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-14445c6a0621.html

Natera (NTRA) CEO Chapman sells 5,838 shares tied to RSU tax obligations

Natera, Inc.'s CEO, Steven Leonard Chapman, sold 5,838 shares of company stock on April 27, 2026. These sales were conducted to cover tax obligations arising from the vesting of Restricted Stock Units (RSUs) and were executed under a pre-arranged Rule 10b5-1 plan, rather than being discretionary trades. Such tax-driven sales generally offer limited insight into management's view of the stock.

https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-b3af82aa8640.html

Trending Today

Roku Inc. ($ROKU) Stock Forecast: Up 5.1% Today

Twilio Inc. Class A ($TWLO) Stock Forecast: Up 5.2% Today

eBay Inc. ($EBAY) Stock Forecast: Up 6.2% Today

Texas Instruments Incorporated ($TXN) Stock Forecast: Up 5.3% Today

Eli Lilly and Company ($LLY) Stock Forecast: Up 9.7% Today

Altria Group Inc. ($MO) Stock Forecast: Up 6.0% Today

Bristol-Myers Squibb Company ($BMY) Stock Forecast: Up 5.1% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Up 6.0% Today

O'Reilly Automotive Inc. ($ORLY) Stock Forecast: Up 8.7% Today

IPG Photonics Corporation ($IPGP) Stock Forecast: Up 5.4% Today

Natera, Inc. Price History

31.02.2026 - NTRA Stock was up 6.5%

• Zevenbergen Capital Investments LLC decreased its stake in Natera, Inc. by 18%, while other institutional investors like Dakota Wealth Management and DAVENPORT & Co LLC have shown increased interest, reflecting diverse sentiments within the market.
• The positive development concerning Natera's Signatera™ MRD test aiding older women with breast cancer to avoid surgery likely contributed to the bullish movement, highlighting the company's advanced and impactful technology.
• Despite recent insider selling, including by the CEO, robust quarterly results surpassing expectations have upheld analyst confidence in Natera, with a "Moderate Buy" consensus and an average price target of $253.47, potentially fueling investor confidence and propelling the stock price higher.
• The decline in Natera's shares on March 30 may have been a temporary setback amidst generally positive sentiment, with Wall Street analysts forecasting a substantial upside and maintaining an "Outperform" recommendation, signaling a possible buying opportunity for investors.

01.03.2026 - NTRA Stock was up 5.1%

• The bullish movement in Natera Inc. (NTRA) today could be attributed to the positive results from the Signatera molecular residual disease (MRD) test, particularly in identifying breast cancer patients who may avoid surgery, boosting investor confidence in the company's innovative technology.
• Despite the recent share sell-off by Zevenbergen Capital Investments LLC, the overall market sentiment remains positive, with increased interest from other institutional investors and strong quarterly results beating expectations, supporting the stock's upward momentum.
• The study showcasing the efficacy of Signatera in guiding treatment decisions for older women with early-stage breast cancer likely contributed to the stock's bullish movement, as it highlights the potential market expansion and adoption of Natera's testing solutions.

14.03.2026 - NTRA Stock was up 5.1%

• William Blair started covering Natera with an Outperform rating, emphasizing the company's market position and growth prospects, likely boosting investor confidence.
• A favorable interim futility analysis from Allogene Therapeutics' trial utilizing Natera's CLARITY™ MRD assay showed promising results in large B-cell lymphoma, contributing to the positive sentiment surrounding Natera.
• A court ruling ordering a 30% ongoing royalty for Natera in a patent dispute is a significant win, reinforcing the company's intellectual property rights and potentially increasing future revenue.
• Despite a decrease in price, the increase in trading volume after the legal victory indicates investor interest and optimism in Natera's future financial performance, as they anticipate the impact of these events on upcoming earnings.

14.03.2026 - NTRA Stock was up 5.8%

• Today's positive performance by Natera is linked to William Blair's initiation of coverage on the company, endorsing its strong position in diagnostic markets and growth potential.
• The encouraging interim futility analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial, which uses Natera's CLARITY™ MRD assay, also contributed to the optimistic outlook by demonstrating successful MRD clearance in high-risk patients.
• Furthermore, a recent court ruling that mandates a 30% ongoing royalty payment to Natera in a patent dispute is seen as a significant victory for the company, reinforcing its intellectual property rights and hinting at future financial gains.
• Despite concerns such as potential overvaluation and insider sales, Natera's leadership in the market, early-mover advantage, and progress in cancer research are likely bolstering investor confidence in its future growth opportunities.

17.03.2026 - NTRA Stock was up 5.1%

• Natera (NTRA) reported impressive fourth-quarter results, exceeding earnings and revenue estimates, which likely boosted investor confidence in the company's performance.
• Positive interim futility analysis from Allogene Therapeutics' ALPHA3 trial, utilizing Natera's CLARITY™ MRD assay, showcased the effectiveness of Natera's technology in identifying high-risk patients and potentially preventing relapse in large B-cell lymphoma cases.
• Despite holding a Zacks Rank #4 (Sell) due to estimate revisions, the initiation of coverage by William Blair with an "outperform" recommendation highlighted Natera's strong position in the growing MRD testing market, projecting significant revenue growth potential.
• The mixed share price performance evaluation, indicating undervaluation by DCF model but overvaluation by P/S ratio, suggests varying perspectives on Natera's future valuation and growth prospects, leaving investors with contrasting views on the stock's true value.

23.03.2026 - NTRA Stock was down 5.2%

• The recent bearish movement in Natera's stock could be attributed to:
• Profit-taking by insiders: Co-founder Sheena Jonathan and family trusts selling a significant number of shares could have indicated a lack of confidence in the short-term performance of the stock.
• Overvaluation concerns: Despite the recent price surge, valuation metrics like the Price-to-Sales (P/S) ratio suggesting overvaluation might have led investors to capitalize on their gains.
• Market dynamics: While Natera's stock experienced a downward trend, other companies in the healthcare sector, such as UFP Technologies, Mettler-Toledo, and Viatris, saw substantial gains, potentially diverting investor attention away from Natera.
• Overall market sentiment: The reopening of the Strait of Hormuz resulting in decreased logistics and energy costs may have redirected investor focus to companies directly benefiting from these changes, impacting Natera's stock negatively.

16.03.2026 - NTRA Stock was down 6.8%

• The bearish movement in Natera's stock today could be attributed to the mixed evaluations of its share price performance, with conflicting assessments of undervaluation and overvaluation.
• Despite being positioned to capture a significant share of the $20 billion MRD opportunity and receiving an 'Outperform' rating from William Blair, concerns about overvaluation and insider selling may have dampened investor sentiment.
• The positive interim results from Allogene Therapeutics’ ALPHA3 trial, showcasing the effectiveness of cema-cel in reducing MRD levels in lymphoma patients, could have been overshadowed by broader market uncertainties or profit-taking activities.
• Natera's strong growth potential and competitive advantages in the diagnostics sector may still underpin its long-term prospects, despite short-term market fluctuations.

09.03.2026 - NTRA Stock was down 5.5%

• The bearish movement in Natera's stock today could be attributed to the Executive Chairman exercising stock options and using shares for taxes. This could have potentially raised concerns among investors about insider activities and the company's financial health.
• Despite Citi maintaining a Buy rating and a target price of $300 for Natera, the market might have reacted negatively to the news of insider selling and the challenges the company faces in profitability.
• The positive sentiment around Natera's upside potential and strong growth of Signatera, as mentioned by billionaire investor Stan Druckenmiller and financial analysts, could be overshadowed by short-term concerns leading to the bearish movement in the stock today.
• Investors will likely keep a close eye on Natera's upcoming earnings and financial performance to gauge its future trajectory, balancing the positive long-term outlook with the immediate challenges the company faces.

30.03.2026 - NTRA Stock was up 5.1%

• The company revealed its first-quarter financial results and held a conference call, potentially boosting investor confidence and fueling the bullish movement.
• Insider selling by the co-founder and CEO, aimed at covering tax obligations, initially raised concerns but a clarified context of these sales being part of a pre-arranged trading plan may have alleviated any negative impact.
• Despite Natera's current lack of profitability, positive court rulings and new analyst coverage could have positively influenced investor sentiment, contributing to the bullish market performance.
• Taken together, positive updates on financial results, structured insider trading activities, and external factors like court decisions and analyst coverage likely played a role in Natera's recent strong bullish trend.

29.03.2026 - NTRA Stock was down 5.0%

• The downward trend in Natera's stock price could be linked to notable insider selling activity by directors such as Roelof Botha, Eric H. Rubin, and Ruth Williams Brinkley. This activity may have sparked concerns among investors regarding the company's future outlook.
• Despite the release of positive information regarding Natera's recent clinical evidence for its Prospera transplant test, which could potentially boost revenue, the overall market sentiment may have been clouded by the insider selling, as well as the company's negative net margins and ROE.
• While the initial increase in M&T Bank Corp's stake could have been viewed as a positive development, investor focus appeared to shift towards the insider selling and the company's financial difficulties, contributing to today's bearish movement in the stock.

10.03.2026 - NTRA Stock was down 5.6%

• The bearish movement in Natera's stock today could be attributed to profit-taking by investors after a recent uptrend following positive legal outcomes.
• The appointment of Director Eric H. Rubin to the insider roster may have raised concerns among investors about potential future decisions or changes within the company.
• Despite the positive rulings in the patent disputes and the increase in royalties, the market may have reacted negatively due to uncertainties surrounding the financial impact on Natera and its competitors.
• The insider activity of the Executive Chairman, Matthew Rabinowitz, exercising stock options and selling shares to cover tax obligations could have also contributed to the downward pressure on the stock price as investors may interpret this as a lack of confidence in the company's future prospects.

10.03.2026 - NTRA Stock was down 7.8%

• The court ruling awarding Natera a 30% royalty on post-injunction revenues from MRD patents against ArcherDx and Invitae was initially seen as a positive development, leading to a slight increase in premarket trading. However, the market may have reacted negatively due to concerns about high cash burn and challenges in clinical trials and reimbursement.
• The addition of director Eric H. Rubin to Natera's insider roster, while providing transparency, did not have a significant impact on the stock movement.
• Despite the favorable court decisions strengthening Natera's intellectual property portfolio, the market may have been influenced by the potential financial implications of the royalty payments on the company's overall performance.
• Analysts revising earnings upwards and the positive influence on stock valuation could indicate long-term growth potential, but the current overvaluation concerns raised in the analysis may have contributed to the bearish market movement.